{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:19:11Z","timestamp":1794633551101,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005289","name":"National Institute of Justice","doi-asserted-by":"publisher","award":["2017-R2-CX-0021"],"award-info":[{"award-number":["2017-R2-CX-0021"]}],"id":[{"id":"10.13039\/100005289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA 000523\\u201313"],"award-info":[{"award-number":["DA 000523\\u201313"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000074","name":"U.S. Department of Justice","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.neuropharm.2021.108800","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T02:10:48Z","timestamp":1632103848000},"page":"108800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-1882","authenticated-orcid":false,"given":"Alex J.","family":"Krotulski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-9155","authenticated-orcid":false,"given":"Amanda L.A.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry K.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108800_bib1","series-title":"Standard Practices for Method Validation in Forensic Toxicology","year":"2019"},{"key":"10.1016\/j.neuropharm.2021.108800_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2019.00321","article-title":"Enantiospecific synthesis, chiral separation, and biological activity of four indazole-3-carboxamide-type synthetic cannabinoid receptor agonists and their detection in seized drug samples","volume":"7","author":"Antonides","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.neuropharm.2021.108800_bib3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.6b00137","article-title":"Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues","volume":"7","author":"Banister","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108800_bib4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acschemneuro.5b00112","article-title":"Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA","volume":"6","author":"Banister","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108800_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.01163","article-title":"Pharmacological and behavioral effects of the synthetic cannabinoid AKB48 in rats","volume":"13","author":"Bilel","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108800_bib6","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1021\/acschemneuro.0c00644","volume":"11","author":"Cannaert","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108800_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/jpet.118.250530","article-title":"Pharmacodynamic effects, pharmacokinetics, and metabolism of the synthetic cannabinoid AM-2201 in male rats","volume":"367","author":"Carlier","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108800_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11419-013-0213-6","article-title":"Synthetic cannabinoids abused in South Korea: drug identifications by the national forensic service from 2009 to june 2013","volume":"32","author":"Chung","year":"2014","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108800_bib9","series-title":"NFLIS-drug 2019 Annual Report","author":"Drug Enforcement Administration","year":"2020"},{"key":"10.1016\/j.neuropharm.2021.108800_bib10","series-title":"Emerging Threat Report Midyear 2018","author":"Drug Enforcement Administration","year":"2018"},{"key":"10.1016\/j.neuropharm.2021.108800_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2018.00055","article-title":"Repeated exposure to the \u201cspice\u201d cannabinoid JWH-018 induces tolerance and enhances responsiveness to 5-HT1A receptor stimulation in male rats","volume":"9","author":"Elmore","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108800_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.118.254425","article-title":"Synthetic cannabinoid hydroxypentyl metabolites retain efficacy at human cannabinoid receptors","volume":"368","author":"Gamage","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108800_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12024-015-9669-5","article-title":"Deaths linked to synthetic cannabinoids","volume":"11","author":"Gerostamoulos","year":"2015","journal-title":"Forensic Sci. Med. Pathol."},{"key":"10.1016\/j.neuropharm.2021.108800_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/dta.2786","article-title":"Impact of legislation on NPS markets in Germany \u2013 the rise and fall of 5F-ADB","volume":"12","author":"Halter","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2021.108800_bib15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/dta.268","article-title":"The emergence and analysis of synthetic cannabinoids","volume":"3","author":"Hudson","year":"2011","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2021.108800_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jat\/bkz092","article-title":"Synthetic cannabinoid deaths in state of Florida prisoners","volume":"44","author":"Hvozdovich","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108800_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11419-017-0361-1","article-title":"In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA","volume":"35","author":"Kevin","year":"2017","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108800_bib18","doi-asserted-by":"crossref","first-page":"110410","DOI":"10.1016\/j.forsciint.2020.110410","article-title":"The synthetic cannabinoid 5F-MDMB-PICA: a case series","volume":"314","author":"Kleis","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2021.108800_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jat\/bkaa054","article-title":"Evaluation of synthetic cannabinoid metabolites in human blood in the absence of parent compounds\u2014a stability assessment","volume":"45","author":"Krotulski","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108800_bib20","series-title":"5F","author":"Krotulski","year":"2018"},{"key":"10.1016\/j.neuropharm.2021.108800_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jat\/bkz084","article-title":"Emerging synthetic cannabinoids: development and validation of a novel liquid chromatography quadrupole time-of-flight mass spectrometry assay for real-time detection","volume":"44","author":"Krotulski","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108800_bib22","series-title":"Positivity of New Synthetic Cannabinoid 4F-MDMB-BICA Increasing in U.S. As Prevalence of 5F-MDMB-PICA Wanes (Public Alert)","author":"Krotulski","year":"2021"},{"key":"10.1016\/j.neuropharm.2021.108800_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.forsciint.2015.12.046","article-title":"Synthetic cannabinoid drug use as a cause or contributory cause of death","volume":"260","author":"Labay","year":"2016","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2021.108800_bib24","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1161\/01.STR.0000079817.68944.1E","article-title":"Drug-induced hypothermia reduces Ischemic damage","volume":"34","author":"Leker Ronen","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2021.108800_bib25","series-title":"Neuropharmacology of New Psychoactive Substances (NPS): the Science behind the Headlines, Current Topics in Behavioral Neurosciences","first-page":"1","article-title":"The growing problem of new psychoactive substances (NPS)","author":"Madras","year":"2017"},{"key":"10.1016\/j.neuropharm.2021.108800_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/dta.2201","article-title":"Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in \u2018legal high\u2019 products and human urine samples: detection of 5F-MDMB-PICA in herbal blends and human urine","volume":"10","author":"Mogler","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2021.108800_bib27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/brainsci10121011","article-title":"Neurochemical and behavioral characterization after acute and repeated exposure to novel synthetic cannabinoid agonist 5-MDMB-PICA","volume":"10","author":"Musa","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2021.108800_bib28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jemermed.2018.09.012","article-title":"Coma, seizures, atrioventricular block, and hypoglycemia in an ADB-FUBINACA body-packer","volume":"55","author":"Nacca","year":"2018","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.neuropharm.2021.108800_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/dta.2517","article-title":"Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors","volume":"11","author":"Noble","year":"2019","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2021.108800_bib30","series-title":"Trend Reports","author":"NPS Discovery","year":"2019"},{"key":"10.1016\/j.neuropharm.2021.108800_bib31","author":"NPS Discovery","year":"2019","journal-title":"Cent. Forensic Sci. Res. Educ."},{"key":"10.1016\/j.neuropharm.2021.108800_bib32","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(19)32231-7","article-title":"New psychoactive substances: challenges for drug surveillance, control, and public health responses","volume":"394","author":"Peacock","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2021.108800_bib33","doi-asserted-by":"crossref","first-page":"172949","DOI":"10.1016\/j.pbb.2020.172949","article-title":"Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: implications for toxicity","volume":"195","author":"Pinson","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108800_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.forsciint.2017.01.023","article-title":"Identification of a new tert-leucinate class synthetic cannabinoid in powder and \u201cspice-like\u201d herbal incenses: methyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (5F-MDMB-PICA)","volume":"273","author":"Risseeuw","year":"2017","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuropharm.2021.108800_bib35","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1111\/bph.14829","article-title":"In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors","volume":"176","author":"Sachdev","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108800_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pnpbp.2012.04.017","article-title":"Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids","volume":"39","author":"Seely","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2021.108800_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/15563650.2016.1186805","article-title":"Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA","volume":"54","author":"Seywright","year":"2016","journal-title":"Clin. Toxicol. Phila. Pa"},{"key":"10.1016\/j.neuropharm.2021.108800_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpba.2017.03.043","article-title":"Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation","volume":"140","author":"Toennes","year":"2017","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.neuropharm.2021.108800_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/dta.2688","article-title":"5F-MDMB-PICA metabolite identification and cannabinoid receptor activity","volume":"12","author":"Truver","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2021.108800_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuropharm.2015.02.008","article-title":"Novel halogenated derivates of JWH-018: behavioral and binding studies in mice","volume":"95","author":"Vigolo","year":"2015","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:37:46Z","timestamp":1777426666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821003555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":40,"alternative-id":["S0028390821003555"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108800","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108800"}}